Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective ...

Scientists have discovered that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, offers a new benefit for ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

FEELING achy, feverish or wiped out? As ‘superflu’ surges across the country, it might be easy to assume you’ve caught the ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...